Cite
HARVARD Citation
Hofheinz, R. et al. (n.d.). 2565 QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice. European journal of cancer. pp. S499-. [Online].